Project Number 5U01AG029213-05 Agency/Funding Organization NIA Funding Year 2012 View Full Project Details for ALZHELMER'S DISEASE DRUG DEVELOPMENT PROGRAM Research Categorization Primary Disease / Condition Alzheimer's Disease Frontotemporal Dementia CADRO Category C. Translational Research and Clinical Interventions 4. Non-clinical Drug Development (small molecules and biologics) b. Tau Researcher and Organization Principal Investigator SMITH, AMOS B Principal Investigator First Name AMOS B Principal Investigator Last Name SMITH Awardee Organization UNIVERSITY OF PENNSYLVANIA Awardee State Pennsylvania Contact PI Country United States Project Detail Funding Opportunity Announcement PAR-05-148: Alzheimer's Disease Drug Development Program FY Overall Cost $591,855 Funding Organization Agency/Funding Organization NIA Funding Organization Country United States Program Official PETANCESKA, SUZANA Related Resources Repository [AlzPED] The microtubule-stabilizing agent, epothilone D, reduces axonal dysfunction, neurotoxicity, cognitive deficits, and Alzheimer-like pathology in an interventional study with aged tau transgenic mice [AlzPED] Epothilone D Improves Microtubule Density, Axonal Integrity and Cognition in a Transgenic Mouse Model of Tauopathy
